CA2991750C - Rpgr gene therapy for retinitis pigmentosa - Google Patents

Rpgr gene therapy for retinitis pigmentosa Download PDF

Info

Publication number
CA2991750C
CA2991750C CA2991750A CA2991750A CA2991750C CA 2991750 C CA2991750 C CA 2991750C CA 2991750 A CA2991750 A CA 2991750A CA 2991750 A CA2991750 A CA 2991750A CA 2991750 C CA2991750 C CA 2991750C
Authority
CA
Canada
Prior art keywords
rpgr
nucleic acid
protein
human
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2991750A
Other languages
English (en)
French (fr)
Other versions
CA2991750A1 (en
Inventor
Michael A. Sandberg
Basil PAWLYK
Alan Finlay WRIGHT
Xinhua SHU
Tiansen Li
Robin Ali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Massachusetts Eye and Ear
US Department of Health and Human Services
Original Assignee
UCL Business Ltd
Massachusetts Eye and Ear Infirmary
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd, Massachusetts Eye and Ear Infirmary, US Department of Health and Human Services filed Critical UCL Business Ltd
Publication of CA2991750A1 publication Critical patent/CA2991750A1/en
Application granted granted Critical
Publication of CA2991750C publication Critical patent/CA2991750C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
CA2991750A 2014-07-24 2015-07-17 Rpgr gene therapy for retinitis pigmentosa Active CA2991750C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028638P 2014-07-24 2014-07-24
US62/028,638 2014-07-24
PCT/US2015/040866 WO2016014353A1 (en) 2014-07-24 2015-07-17 Rpgr gene therapy for retinitis pigmentosa

Publications (2)

Publication Number Publication Date
CA2991750A1 CA2991750A1 (en) 2016-01-28
CA2991750C true CA2991750C (en) 2023-02-14

Family

ID=55163577

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2991750A Active CA2991750C (en) 2014-07-24 2015-07-17 Rpgr gene therapy for retinitis pigmentosa

Country Status (18)

Country Link
US (2) US10314924B2 (enExample)
EP (2) EP3191139B1 (enExample)
JP (3) JP6654760B2 (enExample)
CN (1) CN107206105A (enExample)
CA (1) CA2991750C (enExample)
CY (1) CY1123793T1 (enExample)
DK (2) DK3821912T3 (enExample)
ES (2) ES2834402T3 (enExample)
FI (1) FI3821912T3 (enExample)
HR (2) HRP20241154T1 (enExample)
HU (2) HUE052781T2 (enExample)
LT (2) LT3191139T (enExample)
PL (2) PL3191139T3 (enExample)
PT (2) PT3191139T (enExample)
RS (2) RS61307B1 (enExample)
SI (2) SI3191139T1 (enExample)
SM (2) SMT202000715T1 (enExample)
WO (1) WO2016014353A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3191139T (pt) * 2014-07-24 2020-11-05 Massachusetts Eye & Ear Infirmary Terapia do gene rpgr para retinite pigmentosa
US20190054117A1 (en) * 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
US10646588B2 (en) 2015-03-11 2020-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RP2 and RPGR vectors for treating X-linked retinitis pigmentosa
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
GB201704192D0 (en) 2017-03-16 2017-05-03 Nightstarx Ltd Treatment of Retinitis Pigmentosa
US11723988B2 (en) 2017-10-20 2023-08-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector
WO2019099696A1 (en) * 2017-11-15 2019-05-23 The Regents Of The University Of Michigan Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
JP2023517929A (ja) 2020-03-11 2023-04-27 マサチューセッツ アイ アンド イヤー インファーマリー Ｎｍｎａｔ１関連網膜変性に対する遺伝子療法
CN120350069A (zh) * 2024-01-12 2025-07-22 北京中因科技有限公司 视网膜色素变性动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
DE3851153T2 (de) 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
ATE163046T1 (de) 1990-10-31 1998-02-15 Somatix Therapy Corp Genetische veränderung von endothelzellen
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
AU2044901A (en) 1999-11-24 2001-06-04 Cornell Research Foundation Inc. Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests
GB0008801D0 (en) 2000-04-10 2000-05-31 Medical Res Council Sequences
CN102925445A (zh) * 2011-08-08 2013-02-13 刘军 一种获得rpgr 基因新的转录剪切形式的方法
JP6199965B2 (ja) * 2012-07-11 2017-09-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療
GB201412011D0 (en) 2014-07-04 2014-08-20 Ucl Business Plc Treatments
PT3191139T (pt) * 2014-07-24 2020-11-05 Massachusetts Eye & Ear Infirmary Terapia do gene rpgr para retinite pigmentosa

Also Published As

Publication number Publication date
EP3191139A1 (en) 2017-07-19
WO2016014353A1 (en) 2016-01-28
US11045558B2 (en) 2021-06-29
JP2022009333A (ja) 2022-01-14
HRP20241154T1 (hr) 2024-11-22
HUE068183T2 (hu) 2024-12-28
RS61307B1 (sr) 2021-02-26
HRP20202023T1 (hr) 2021-03-05
EP3821912A1 (en) 2021-05-19
HUE052781T2 (hu) 2021-05-28
SMT202400309T1 (it) 2024-11-15
FI3821912T3 (fi) 2024-08-05
PL3821912T3 (pl) 2024-10-28
DK3821912T3 (da) 2024-08-05
EP3191139B1 (en) 2020-10-07
ES2834402T3 (es) 2021-06-17
PL3191139T3 (pl) 2021-07-05
PT3821912T (pt) 2024-08-01
US20170216454A1 (en) 2017-08-03
SI3191139T1 (sl) 2021-03-31
DK3191139T3 (da) 2020-11-16
CA2991750A1 (en) 2016-01-28
US20200215203A1 (en) 2020-07-09
CN107206105A (zh) 2017-09-26
LT3191139T (lt) 2021-01-25
ES2987090T3 (es) 2024-11-13
CY1123793T1 (el) 2022-05-27
LT3821912T (lt) 2024-09-25
PT3191139T (pt) 2020-11-05
JP2017523239A (ja) 2017-08-17
JP7198329B2 (ja) 2022-12-28
JP2020073536A (ja) 2020-05-14
EP3821912B1 (en) 2024-06-12
US10314924B2 (en) 2019-06-11
SI3821912T1 (sl) 2024-10-30
SMT202000715T1 (it) 2021-01-05
EP3191139A4 (en) 2018-01-10
JP6966532B2 (ja) 2021-11-17
JP6654760B2 (ja) 2020-02-26
RS65909B1 (sr) 2024-10-31

Similar Documents

Publication Publication Date Title
US11045558B2 (en) RPGR gene therapy for retinitis pigmentosa
Pawlyk et al. Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of X-linked retinitis pigmentosa
Yin et al. Intravitreal injection of AAV2 transduces macaque inner retina
RS62359B1 (sr) Lečenje amd upotrebom aav sflt-1
KR20170054493A (ko) 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터
CN119731328A (zh) Abca4反式剪接分子
Bouaita et al. Downregulation of apoptosis-inducing factor in Harlequin mice induces progressive and severe optic atrophy which is durably prevented by AAV2-AIF1 gene therapy
US20140364488A1 (en) Rpgrip1 gene therapy for leber congenital amaurosis
US20230139443A1 (en) Treating autosomal dominant bestrophinopathies and methods for evaluating same
HK40051900A (en) Rpgr gene therapy for retinitis pigmentosa
HK40051900B (en) Rpgr gene therapy for retinitis pigmentosa
CN113795279B (zh) 靶向akt通路的神经保护性基因疗法
WO2024073093A2 (en) Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells and tissues of the eye
Duong Use Of Induced Pluripotent Stem Cell Models To Elucidate Retinal Disease Pathogenesis And To Develop Gene-Based Therapies
Matsuki Development of gene therapy for achromatopsia due to CNGA3 mutations
Tan Development of gene therapy for the treatment of retinal dystrophies caused by mutations in AIPL1
Tracy Ex Vivo Gene Therapy for the Preservation of Retinal and Central Nervous System Structure and Function in a Canine Model of CLN2 Neuronal Ceroid Lipofuscinosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250708

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250708